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Summary
Glucocorticoid (GC) resistance is a continuing clinical problem in child-
hood acute lymphoblastic leukaemia (ALL) but the underlying mechanisms
remain unclear. A proteomic approach was used to compare profiles of the
B-lineage ALL GC-sensitive cell line, PreB 697, and its GC-resistant sub-
line, R3F9, pre- and post-dexamethasone exposure. PAX5, a transcription
factor critical to B-cell development was differentially regulated in the PreB
697 compared to the R3F9 cell line in response to GC. PAX5 basal protein
expression was less in R3F9 compared to its GC-sensitive parent and con-
firmed to be lower in other GC-resistant sub-lines of Pre B 697 and was
associated with a decreased expression of the PAX5 transcriptional target,
CD19. Gene set enrichment analysis showed that increasing GC-resistance
was associated with differentiation from preB-II to an immature B-lympho-
cyte stage. GC-resistant sub-lines were shown to have higher levels of
phosphorylated JNK compared to the parent line and JNK inhibition
caused re-sensitization to GC. Exploiting this maturation may be key to
overcoming GC resistance and targeting signalling pathways linked to the
maturation state, such as JNK, may be a novel approach.
Keywords: iTRAQ proteomics, glucocorticoid resistance, childhood acute
lymphoblastic leukaemia, B cell differentiation, JNK signalling.
Acute lymphoblastic leukaemia (ALL) is the most common
cancer in children and is characterized by the clonal expan-
sion of poorly differentiated lymphoid precursors within the
bone marrow. The treatment of ALL is a highly complex
protocol comprising several chemotherapeutic agents, of
which glucocorticoids (GCs) are integral due to their ability
to specifically induce apoptosis in immature lymphoid cells
(Gaynon & Carrel, 1999). These effects are mediated by the
glucocorticoid receptor (GR, encoded by NR3C1), a ligand-
activated transcription factor belonging to the nuclear recep-
tor superfamily. Once bound to ligand, the GR translocates
to the nucleus where it mediates GC-induced cell death by
transactivation or transrepression of target genes.
Although current chemotherapy protocols successfully
cure most childhood ALL cases, treatment still fails approxi-
mately 15% (Pui et al, 2012). This treatment failure can
often be attributed to the development of chemotherapy
resistance and response to GCs in vitro and in vivo has been
shown to be one of the most significant prognostic indicators
of event outcome (Riehm et al, 1987; Reiter et al, 1994;
Schrappe et al, 2000). GC-resistance is a well-documented
feature of relapse, with leukaemic cells being up to 300-fold
more resistant to GC in vitro compared to those at diagnosis
(Klumper et al, 1995; Kaspers et al, 2005). Furthermore, leu-
kaemic cells from high-risk groups, such as T-ALL, infant
ALL and adult ALL, are more resistant to GCs in vitro
(Maung et al, 1995; Pieters et al, 1998). However, despite
their important role of GC in all ALL treatment protocols,
the mechanisms underlying GC resistance are poorly under-
stood and remain a continuing clinical problem.
In most in vitro cell line models of childhood ALL, such
as Jurkat and CCRF-CEM, a common cause of GC-therapy
research paper
ª 2015 The Authors. British Journal of Haematology published by John Wiley & Sons Ltd.
British Journal of Haematology, 2015, 171, 595–605
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium,
provided the original work is properly cited.
First published online 27 August 2015
doi:10.1111/bjh.13647
resistance is mutation/deletion of the NR3C1 gene (encoding
GR), causing impaired receptor function (Powers et al, 1993;
Hala et al, 1996; Schmidt et al, 2006). However, acquired
somatic mutations or deletions of the NR3C1 rarely occur in
primary samples and thus, cannot account for most cases of
GC-insensitivity (Irving et al, 2005; Tissing et al, 2005; Kus-
ter et al, 2011). Therefore, this opens up the possibility that
understanding the mechanisms underlying GC-resistance
may allow its pharmacological reversal and improve out-
come. Microarray analyses comparing gene expression pro-
files of GC-sensitive ‘versus’ GC-resistant cell lines and
primary ALL samples have yielded important, yet limited,
information of the pathways leading to this drug insensitiv-
ity. A review by Schmidt et al (2004) reported that although
900 different genes were identified as GC-regulated, only 70
genes were reproduced in more than one publication. This
suggests that RNA-based methods may be limiting and there
is growing evidence that levels of mRNA transcripts do not
necessarily reflect protein amounts (Unwin et al, 2006).
Proteomic technologies are rapidly emerging as useful
tools to gain insight into complex biological systems at the
level of protein expression. One discovery proteomic
approach uses isobaric Tags for Relative and Absolute Quan-
tification (iTRAQ proteomics), coupled with two-dimen-
sional liquid chromatography/tandem mass spectrometry
(LC-LCMS/MS). The iTRAQ method relies on differentially
labelling peptides from individual proteolytic digests by cova-
lent binding of isobaric tags and allows identification and
quantification of peptides in multiple samples in a single
experiment (Unwin et al, 2005). Using this methodology, we
compared a well-characterized GC-sensitive cell line, PreB
697, and a GC-resistant sub-clone (R3F9) in response to 24-
h exposure to a pharmacologically-relevant dose of dexam-
ethasone (01 lmol/l). We have previously shown that both
cell lines recapitulate several features of GC-resistant primary
samples, including having two wild type NR3C1 alleles,
expressing equivalent levels of GR protein and undergoing
GR nuclear translocation in response to Dex but with
reduced induction of GR target genes in the resistant subline
(Nicholson et al, 2010). We report that the critical mediator
of B-cell lineage commitment, PAX5, is differentially
expressed between GC-sensitive and GC-resistant clones and
is associated with maturation, JNK activation and that re-
sensitization to GC can be achieved by JNK inhibition.
Materials and methods
Cell lines
The PreB lineage childhood ALL cell line PreB 697 (recently
re-named EU-3 by the original author (Zhou et al, 2002)
and also referred to as ‘697’ in cell line repositories) and its
GC-resistant descendents, R3C3, R3G7, R3F9, R4C10 and
R3D11, were created by continuous culture in 107mol/l
dexamethasone for 3–4 weeks (Schmidt et al, 2006). Dexam-
ethasone GI50 values (i.e. the dexamethasone concentration
that results in 50% of maximal inhibition of cell prolifera-
tion) at 96 h, as measured by MTS (3-(4,5-dimethylthiazol-
2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-te-
trazolium) assay, are 37 nmol/l (PreB 697), 86 nmol/l
(R3C3), 132 lmol/l (R3G7), 143 lmol/l (R4C10) and
>10 lmol/l (R3F9, R3D11). Other cell lines were obtained
from European Collection of Cell Cultures (Salisbury, UK)
or the American Tissue Culture Collection (Manassas, VA,
USA) and all were cultured in RPMI 1640 medium (Invitro-
gen, Paisley, UK) supplemented with 10% (v/v) foetal bovine
serum (Invitrogen) at 37°C and 5% (v/v) carbon dioxide. All
cell lines were routinely tested for mycoplasma contamina-
tion using MycoAlert (Lonza, Basel, Switzerland).
Proteomics methods
Detailed proteomic methods are shown in the supplementary
material.
Western blotting
Whole cell lysates were prepared using cell lysis buffer
(50 mmol/l Tris-HCl, pH 75, 150 mmol/l NaCl, 1% Triton
X-100, 05% Na-deoxycholate, 01% sodium dodecyl sul-
phate) supplemented with protease inhibitor cocktail (Roche,
West Sussex, UK). Antibodies to detect PAX5 (E-9) (Santa
Cruz Biotechnology, Santa Cruz, CA, USA), a-Tubulin
(Sigma-Aldrich), IRF4, phospho-SAPK/JNK (Thr183/
Tyr185), SAPK/JNK (all Cell Signaling Technology, Danvers,
MA, USA) were used. Secondary antibodies used were horse-
radish peroxidase conjugates of either anti-rabbit or anti-
mouse IgG (both Dako, Glostrup, Denmark). Quantification
was carried out by imaging the enhanced chemiluminescence
(ECL)-plus exposed polyvinylidene difluoride membranes
using the Fuji LAS-3000 Luminescent Image Analyser System
(Fujifilm, Tokyo, Japan) and analysing the intensity of the
protein bands using an Automatic Image Data Analysis
(AIDA) software image analysis program (Fujifilm). PAX5
basal protein levels in the cell lines were calculated by divid-
ing the intensity of the PAX5 protein band by the intensity
of the loading control, a-tubulin, band, thereby normalizing
for any loading inaccuracies.
Real-time polymerase chain reaction (PCR)
Briefly, total RNA was extracted from cell pellets using the
Qiagen RNeasy Mini kit (Qiagen, Crawley, UK) and cDNA
synthesis was carried out using the Applied Biosystem High-
Capacity cDNA Reverse Transcriptase kit according to the
manufacturer’s instructions. Primers and probes for PAX5
(Hs00277134_m1) and TATA-binding protein (TBP) were
purchased from Assays-On-Demand (Applied Biosystems,
Warrington, UK). Samples were assayed in duplicate on three
independent occasions with the ABI 7500 Fast Real-Time
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PCR System (Applied Biosystems) using the TaqManuni-
versal PCR MasterMix (Applied Biosystems). To quantify
mRNA levels the 2DCT or 2DDCT method was used with
TBP as the endogenous control, as indicated.
PAX5 copy number analysis with quantitative genomic
PCR
This assay was performed as described in An et al (2008)
with ATP10A as the control gene. Briefly, 5-point standard
curves ranging from 150 ng to 1 ng/reaction were con-
structed using normal human genomic DNA and amplified
for the 3 target PAX5 exons (exons 3, 6, and 8) and control
ATP10 gene. Assays were performed in duplicate with 50 ng
of genomic DNA from each cell line per 20 ll reaction, using
an ABI 7500 Fast Real-Time PCR System (Applied Biosys-
tems). PAX5 gene dosage for each exon was calculated by
dividing the value obtained for PAX5 by the corresponding
value for ATP10A.
Mutational screening
PAX5 exons 2-10 were mutationally screened by direct DNA
sequencing. Briefly, genomic DNA was extracted from cell
lines using the Qiagen Mini kit (Qiagen) and amplified by
PCR. Primer sequences and annealing temperatures are
shown in Table SI. DNA sequencing was performed by puri-
fying 100 ll of PCR product using a QIAquick PCR Purifica-
tion kit (Qiagen) with a final elution volume of 30 ll and
then sequenced using both forward and reverse primers with
the ABI Version 3 BigDye Terminator Cycle Sequencing kit
and analysed on an ABI Prism DNA sequencer (Applied
Biosystems).
Multiplex ligation-dependent probe amplification
(MLPA)
Cell line DNA was analysed using the SALSA MLPA kit
P335-A2 (MRC Holland, Amsterdam, Netherlands) as
described previously (Schwab et al, 2010). Relative copy
number was obtained after normalization of peaks against
known normal control samples extracted by the same
method. Values between 075 and 13 were considered to
be within the normal range. Values below 075 or above
13 indicated loss or gain, respectively. A value below 025
indicated biallelic loss. These values correspond to copy
numbers of 1, 3+ or 0, respectively, with 2 being the nor-
mal copy number.
In vitro drug sensitivity
Cells were plated out in triplicate at 2 9 105 cells/ml into
96-well plates and treated with dexamethasone to a range of
final concentrations, as indicated, either alone, or in combi-
nation with 5 lmol/l JNK inhibitor, SP600125 (Selleckchem,
distributed via Stratech Scientific Ltd, Suffolk, UK) or 2-
5 nmol/l Bortezomib (Selleckchem). Following a 96-h drug
exposure, cytotoxicity was assessed using the CellTiter 96
Aqueous One kit (Promega, Southampton, UK), also known
as MTS assay, which assesses the capacity of cells to reduce
formazan and thus is a measure of metabolically active cells.
The resulting absorbances were averaged and expressed as a
percentage of the control vehicle. Survival curves were plot-
ted using GraphPad Prism software (GraphPad software Inc.,
San Diego, CA, USA). Drug interactions were assessed using
the Chou-Talalay method, which is based on the median
effect equation (Chou & Talalay, 1984).
Flow cytometry
Cell surface CD antigen expression: Cells were stained with
directly conjugated antibodies to CD19-allophycocyanin
(APC) and CD10-phycoerythrin (PE) or the corresponding
isotype control. Ten thousand events for each sample were
acquired using a FACSCalibur flow cytometer (BD Bio-
sciences, Oxford, UK) and analysed using CellQuest software
(BD Biosciences) on three independent occasions.
Annexin V assays for apoptosis. Cells were stained with
Annexin V (Abcam, Cambridge, UK) and evaluated for
apoptosis by flow cytometry following the manufacturer’s
protocol. Ten thousand events for each sample were acquired
using a FACSCalibur flow cytometer (BD Biosciences) and
analysed using CellQuest software (BD Biosciences).
Exon array and gene set enrichment analysis (GSEA)
Total RNA was harvested and extracted using the Qiagen
RNeasy Mini kit according to the manufacturer’s intructions
and subjected to expression profiling using Affymetrix Human
Exon 1.0 ST GeneChips (Affymetrix, Santa Clara, CA, USA).
Exon microarray hybridization and pre-processing was carried
out as previously described (Rainer et al, 2012). Raw and
pre-processed microarray data has been deposited in Gene
Expression Omnibus, accession number GSE63335. GSEA was
performed using the standalone application (Broad Institute,
Cambridge, MA, USA) and MSIGDB library C2.v3.1 (http://
www.broadinstitute.org/gsea/msigdb/index.jsp). Genes were
pre-ranked according to their Pearson correlation with 50%
inhibitory concentration (IC50) values for individual PreB 697
cell lines.
Statistical analysis
Graph plotting and statistical analyses were performed using
GraphPad Prism version 4 (GraphPad software Inc.). Each
experiment was repeated at least three times, unless indi-
cated. The P values were calculated using a two-tailed paired
Student’s t test or two-way ANOVA where appropriate. Sta-
tistical significance was defined as a P value ≤005.
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Results
iTRAQ quantitative analysis identifies differences in
PAX5 protein levels between GC-sensitive PreB 697 cell
line and GC-resistant R3F9 cell line in response to 24-h
Dexamethasone exposure
To identify differentially expressed, low abundance, nuclear
proteins related to GC-resistance, nuclear lysates from
untreated and dexamethasone-treated (DEX) or ethanol con-
trol vehicle (CV) were prepared from PreB 697 and R3F9
cells. Lysates were labelled with a distinct isobaric tag for
relative quantification and analysed by two dimensional
liquid chromatography/tandem mass spectrometry (PreB
697 + CV = 114 isobaric tag, PreB 697 + DEX = 115,
R3F9 + CV = 116 and R3F9 + DEX = 117). In total, 811
unique proteins were identified at greater than 95% confi-
dence, most of which did not show any differential expres-
sion between samples (Tables SII and SIII).
Ratios were calculated for dexamethasone-treated ‘versus’
control vehicle for each cell line. Data mining of the Excel
spreadsheets (see Tables SIIA, B and SIIIA, B) identified a
number of proteins differentially expressed between cell lines
and treated ‘versus’ control. Figure 1A-D shows the expres-
sion of proteins involved in different cellular processes that
were either up- or down-regulated after dexamethasone-
treatment in the PreB 697 (Fig 1A and B, respectively) and
R3F9 (Fig 1C and D, respectively). Unsurprisingly, given the
use of nuclear lysates, the biological function that showed
the biggest protein change in each comparison was nucle-
oside, nucleotide and nucleic acid metabolism. Within this
group, the top 2 proteins found to be differentially upregu-
lated in the GC-sensitive parental cell line compared to the
resistant sub-line was SMAD4 (P = 0001) and PAX5
(P = 002). For PAX5, a single peptide (amino acid sequence:
ANLASPTADIGSSVPGPQSYPIVTGR) was identified in all
four samples (697 Dex: 697 CV, iTRAQ ratio of 181,
P = 002, compared to 090, P = 014, for R3F9, Figure S1
and Table SIV). A second B cell transcription factor, IRF4,
based on two peptide sequences (LFDTQQFLSELQA-
FAHHGR and LITAHVEPLLAR) was also identified to be
differentially unregulated in the GC-sensitive cell line, but
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Fig 1. Protein changes in PreB 697 and R3F9 cells in response to dexamethasone treatment. Proteins that showed significant changes (Up and
Down) in expression levels in response to 24 h 01 lmol/l dexamethasone-treatment in PreB 697 (A, B) and R3F9 (C, D) cells, classed according
to biological function by entering their protein identification numbers into the PANTHER (Protein Analysis Through Evolutionary Relationships)
classification system.
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did not achieve statistical significance (697 Dex: 697 CV,
iTRAQ ratio of 139, P = 019), while the IRF4 levels in the
treated R3F9 cell line remained unchanged (Dex: R3F9 CV,
iTRAQ ratio of 102, P = 084). This differential upregulation
of IRF4 and PAX5 in response to GC in the sensitive com-
pared to the resistant line was verified by Western blot (Fig 2
and Figure S2). Conversely, for SMAD4, differential upregu-
lation could not be confirmed by Western analyses (data not
shown).
Parallel real-time quantitative reverse transcription PCR
(RQ-PCR) and Western blotting analyses showed that PreB
697 cells significantly upregulated PAX5 in response to dex-
amethasone, both at the mRNA (P = 0016, 0 vs. 24 h by
Student’s t-test) and protein level at 24 h, while R3F9 cell
line failed to upregulate PAX5 significantly at either the
mRNA (P = 0299) or protein level (Fig 2A). Importantly, it
was noted that R3F9 had a reduced PAX5 protein expression
at a basal, untreated level, in comparison to its GC-sensitive
parental cell line. Other GC-resistant sub lines derived from
PreB 697 previously characterized for GC sensitivity and GR
status (Nicholson et al, 2010) including R3C3, R3G7, R3F9
and R4C10, (GI50 range 861 nmol/l to >10 lmol/l; GR wild
type; normal GR levels) also showed reduced basal and
induced PAX5 levels, relative to the GC-sensitive parent
(Fig 2B and Figure S3). An exception was R3D11
(GI50 > 10 lmol/l; GR wild type) but this cell line, as we
have previously shown, is GR deficient (Nicholson et al,
2010). These data suggest that the B cell transcription factors,
PAX5 and IRF4, are transcriptional targets of GR and that
lower PAX5 basal protein expression is associated with a GC-
resistant phenotype.
Lower PAX5 protein levels in GC-resistant sub-clones is
a post-transcriptional effect that has functional
consequences
Recent studies have shown that PAX5 inactivation, most
commonly due to deletion or point mutation, is a frequent
occurrence in B-progenitor cases of ALL and results in a cor-
responding loss or disruption of the PAX5 protein (Mul-
lighan et al, 2007). Thus, to investigate likely mechanisms for
decreased expression of PAX5 protein in the GC-resistant
sub-lines, RQ-PCR for gene copy number and mutational
screening of all coding exons was performed in PreB 697 and
its GC-resistant derivatives. There was no evidence for
decreased allele copy number in the resistant lines (exon 3,
P = ≥0232; exon 6, P = ≥0468; exon 8, P = ≥0242)
(Fig 3A, B and C, respectively) and mutational screening
found no evidence for acquired mutations in the resistant
lines. The identification of a common single nucleotide poly-
morphism (rs2297105) in exon 2, found to be heterozygous
in all lines, is further evidence that GC-resistant sub lines,
like the parent line, have two intact wild type PAX5 alleles
and MLPA also detected a normal copy number for PAX5
along with IKZF1, CDKN2A/B, ETV6, BTG1, RB1 and the
PAR1 region in all 6 cell lines. EBF1 showed gain (3-5
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copies) in exons 10, 14, and 16 but showed a normal copy
number for exon 1 for all 6 cell lines (Figure S4).
RQ-RT-PCR of PAX5 showed that mRNA levels were sim-
ilar in all cell lines (p = >02251) (Fig 3D), suggesting that
the reduced PAX5 protein level in GC-resistant sub-lines is
post-transcriptional. Protein stability experiments showed no
apparent difference in the half-life of the PAX5 protein in
GC-sensitive compared to GC-resistant cell lines (Figure S5).
To assess the functional consequences of lower PAX5 protein
levels, the principal transcriptional target of PAX5, CD19,
was assessed by flow cytometry (Fig 3E). As expected, the
parental cell line, PreB 697, had the highest level of CD19
expression, with lower levels in 3 out of the 4 GC-resistant
sub-lines, which was statistically significant for R3F9 and
R3C3 (P = 0023 and 0007, respectively) but not for R3G7
(P = 0219). Again, the GR-deficient RD11 cell line with nor-
mal levels of PAX5 had similar CD19 levels to the GC-sensi-
tive parent.
GC resistance is associated with increased B-cell maturity
in the PreB 697 cell line model
As PAX5 is integral to B-cell commitment and differentia-
tion, we investigated whether the reduced levels of PAX5 are
a reflection of an altered maturation state by using gene
expression arrays. GSEA was used to analyse the state of dif-
ferentiation of GC-resistant sub-lines and genes were ranked
according to the correlation of gene expression with dexam-
ethasone IC50 values for the individual sub-lines. A set of
genes whose expression describes the transition from a preB-
II differentiation state to immature B-lymphocytes, was sig-
nificantly enriched in the GC-resistant sub-lines; Normalized
Enrichment Score = 196, P = 0001, q = 016 (Fig 4).(Hoff-
mann et al, 2002) Thus increasing GC-resistance is coupled
to a single step in B cell maturation and was further con-
firmed by additional immunophenotyping that demonstrated
a significant decrease in CD10 basal expression in 3 of 4 GC
resistant sub lines (Figure S6; P < 0005). All cell lines were
found to be negative for CD20 expression, a mature B cell
differentiation marker, and also the stem cell marker, CD34
(data not shown).
GC resistance is associated with JNK activation and
inhibition re-sensitizes GC response
Given that activation of the JNK pathway has been associated
with GC resistance (Miller et al, 2007; Garza et al, 2009) and
degradation of proteins (Leung et al, 2008), we assessed
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Fig 3. Lower PAX5 levels in GC-resistant sub-clones is post-transcriptional and functional. (A–C) Quantification of PAX5 gene expression by
real-time genomic PCR to assess copy number loss. Levels of PAX5 exons 3, 6 and 8 were quantified and PCR results were expressed as a ratio of
PAX5/ATP10A. Ratios of less than 07 defined a deletion. (D) Quantification of basal PAX5 mRNA expression by quantitative real-time PCR.
Levels were normalized to an endogenous control, TBP, by the 2DCt method. The histogram shows mean  SEM from at least three indepen-
dent experiments. (E) FACS analysis of CD19 expression in the GC-sensitive, PreB 697, and four GC-resistant ‘R’ clones. Data plotted are the
mean fluorescence intensity (MFI) and is the ratio between the CD19 MFI and isotype control MFI. Error bars represent the SEM of triplicate
experiments; statistical significance was assessed with a paired t test *P < 005, **P < 0005.
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levels of phosphorylated JNK (pJNK) both basally and in
response to dexamethasone in PreB 697 and R3F9 cells. Basal
levels of pJNK were significantly elevated in the GC-resistant
cell line compared to the PreB 697 cells (Fig 5A) and GC
reduced the low level pJNK in these sensitive but not resis-
tant cells. Higher basal pJNK levels were also evident in the
other GC-resistant cell lines (Figure S7). Using a non-toxic
dose (5 lmol/l, Figure S8) of the pan-specific JNK inhibitor,
SP600125 in combination with dexamethasone, there was a
30-fold increase in GC sensitivity in R3F9 cells, with an IC50
of >10 lmol/l lowering to 273 nmol/l (P < 00001) and a
modest sensitization was also seen in the sensitive parent
line, 80–24 nmol/l (P < 00001) (Fig 5B and C). The combi-
nation index in R3F9 was indicative of strong synergy and
this sensitization was also seen in other GC resistant cell lines
(Figure S9) and was associated with increased numbers of
apoptotic cells, as measured by annexin V binding (Fig 5D
and E) and JNK inhibition (Fig 5F). In addition, SP600125
alone increased levels of PAX5 in all cell lines (Fig 5G), sug-
gesting a link between JNK activation, PAX5 levels, matura-
tion and GC resistance. The proteasome inhibitor,
Bortezomib was not able to mirror these effects (Figure S10).
As JNK activation has also been associated with GC resis-
tance in T ALL, (Miller et al, 2007) we explored GC sensitiza-
tion by JNK inhibition in a panel of T ALL lines and found
significant sensitization in all four cell lines (Figure S11).
Discussion
This is the first study to couple a discovery proteomic/mass
spectrometry approach with a GC-resistant ALL model sys-
tem. It has identified differential expression of PAX5, both
basally and in response to GC, in a GC-sensitive compared
to GC-resistant sub-line. Importantly, this finding was subse-
quently confirmed in additional GC-resistant sub-lines. The
PAX family of transcription factors have a DNA-binding
paired-box and homeobox domain and act as crucial regula-
tors of tissue development, cell proliferation, migration and
survival. PAX5 is the only member to be expressed within
the haematopoietic system and is indispensable in the com-
mitment of early lymphoid progenitors to the B-cell lineage
and maintenance of B-cell identity (Cobaleda et al, 2007;
Nutt & Kee, 2007). Its role as a tumour suppressor in leukae-
mogenesis has recently gained prominence in that PAX5
inactivation has been shown to be one of the most common
genetic alterations in pre-B ALL and results in a reversible
differentiation block (Mullighan et al, 2007, 2008, 2009; Neb-
ral et al, 2009; Liu et al, 2014).
The lower basal PAX5 levels in GC-resistant lines, together
with gene expression profiling and lowering CD19 and CD10
are indicative of increased B cell maturation that the sub
lines have acquired to evade GC-induced apoptosis. The
maturation state of a B cell has an inverse relationship with
sensitivity to both synthetic and endogenous GCs, with early
B-cell progenitors readily undergoing apoptosis compared to
more mature B cells (Lill-Elghanian et al, 2002; Igarashi et al,
2005). Physiologically, this may serve to regulate steady-state
lymphopoiesis (Lill-Elghanian et al, 2002), as well as control-
ling positive selection in thymocytes to prevent autoreactive
T-cells (Vacchio & Ashwell, 1997). Although our study
focuses on cell lines and not primary cells, this phenomenon
of GC-resistance maturation has been observed in clinical
Fig 4. GSEA reveals a more mature B-cell gene
expression pattern in the GC-resistant clones.
Plot showing significant enrichment in GC-re-
sistant sub-clones of PreB 697 of a set of genes
whose expression is upregulated during the
transition from pre-BII to immature B-lym-
phocytes. Vertical lines show the position in
ranking of genes of individual genes in the
gene set. NES, Normalized Enrichment Score.
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samples: Rhein et al (2007) showed that ALL cells persisting
in vivo after 8 d of GC-monotherapy had acquired a more
mature B-cell phenotype and, in a study by Dworzak et al
(2008), CD20, a B cell differentiation antigen, was upregu-
lated after prednisolone exposure in residual blasts in some
patients. An important difference we show here is that the
maturation was a subtle one-step progression from preB-II
towards immature B-lymphocytes, but prior to upregulation
of CD20. While we have investigated acquired GC resistance,
it is also possible that maturation influences primary GC
response as a study of gene expression profiling of leukaemia
cells from children with a poor prednisolone response in vivo
showed lower levels of genes important in B-cell develop-
ment, prior to treatment. (Cario et al, 2008).
The increased maturation state in GC resistance sublines
was associated with reduced PAX5 levels and enhanced JNK
signalling. While little is known about the regulation of
PAX5 protein levels, our data implicates the JNK pathway in
modifying PAX5 protein levels and indeed other PAX family
members have been shown to be substrates of JNK (Cai et al,
2003; Boutet et al, 2007). JNK inhibition significantly sensi-
tized very resistant ALL cells to GC by 30-fold and reduced
the GI50 of these cells to clinically achievable dexamethasone
levels and at concentrations that clearly inhibited JNK sig-
nalling. In T-ALL cells, JNK activation has also been shown
to be associated with etoposide resistance through a mecha-
nism that involved direct phosphorylation of Bim(EL) (also
termed BCL2L11) by JNK, which triggered proteasomal
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Fig 5. JNK signalling is aberrant in GC-resistant clones and inhibition can re-sensitize. Western analyses of PreB 697 and R3F9 cells treated with
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lysate were probed using antibodies targeting phosphorylated JNK (p-JNK) and JNK. GC-sensitive (PreB697, B) and -resistant (R3F9, C) cells
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degradation; JNK inhibitors were similarly able to re-sensitize
to this drug (Leung et al, 2008). Thus, our observed GC-re-
sensitization by JNK inhibition may be similarly mediated
through direct phosphorylation of Bim, and may also co-sen-
sitize to other chemotherapeutics agents. Miller et al (2007)
also implicated JNK activation levels in determining GC
response in T ALL cells, which we confirm. They showed the
mechanism to involve modulation of GR transcriptional
activity by JNK. Thus, JNK inhibition, or a key downstream
JNK target, may allow GC sensitization in both B- and T-lin-
eage ALL. Our data adds to the increasing evidence that
MAPK pathways modulate GC response in ALL cells and,
more recently, anisomycin, a protein synthesis inhibitor and
p38 (also termed MAPK14) agonist, was shown to resensitize
GC response via activation of both p38 and JNK (Miller
et al, 2007; Garza et al, 2009; Liu et al, 2013).
In conclusion, we report the first study to use discovery
proteomics to investigate GC-resistance in a childhood ALL
cell line model and identify subtle single step maturation as a
recurrent mechanism in a cell line model. Exploiting this
maturation may be key to overcoming GC resistance and
might involve antibody therapies, such as Rituximab, if
CD20 is induced (Dworzak et al, 2008) or, as we show, tar-
geting signalling pathways linked to the maturation state,
such as JNK.
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